Drugs / NasoShield
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04415749 | Jun 2020 → Mar 2021 | — | Altimmune, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03352466 | Jan 2018 → May 2019 | — | Altimmune, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NasoShield | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04415749 ↗ |
| Modality | Vaccine | “NasoShield is an adenovirus-vectored anthrax vaccine.” NCT03352466 ↗ |
| Route | Intranasal | “1 intranasal dose of NasoShield” NCT03352466 ↗ |